Long non-coding RNA CCAT2 as a potential serum biomarker for diagnosis and prognosis of multiple myeloma

• Published in: Annals of hematology Vol. 99; no. 9; pp. 2159 - 2171
• Main Authors: Xu, Honglei, Yin, Qingqing, Shen, Xianjuan, Ju, Shaoqing
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2020; Springer Nature B.V
• Subjects: Hematology; Medical diagnosis; Medical prognosis; Medicine; Medicine & Public Health; Multiple myeloma; Oncology; Original Article; Clinical value; Serum; Biomarker; lncRNA CCAT2; Multiple myeloma
• ISSN: 0939-5555; 1432-0584
• DOI: 10.1007/s00277-020-04161-9

Increasing knowledge of long non-coding RNAs (lncRNAs) has shown that they can be used as circulating tumor markers. Also, considerable evidences have revealed that lncRNAs have important roles in tumor diagnosis and prognosis. The lncRNA CCAT2 has manifested its carcinogenic effect in a variety of tumors, but the serum expression level and clinical value in multiple myeloma (MM) remain to be explored. In our study, the expression of lncRNA CCAT2 is upregulated in the serum and bone marrow of MM patients by using quantitative real-time polymerase chain reaction (qRT-PCR). The high expression level of CCAT2 in the serum of MM patients correlated with International Scoring System (ISS) stages, renal dysfunction, serum β 2 -microglobulin (β 2 -MG) concentration, and light chain (κ and λ) concentrations. Area under the curve (AUC) of CCAT2 in serum is 0.899. Besides, the sensitivity and specificity were 85.80% and 83%, respectively. Furthermore, combination of CCAT2, IgA, HGB, and β 2 -MG significantly improved the MM diagnostic sensitivity and AUC. Here, our present investigation indicates that serum circulating CCAT2 may serve as a potential tumor marker for diagnosis and prognosis of MM.